Corindus Vascular Robotics (NYSE American:CVRS) privately sold 10,872,716 of its common shares at a price of $1.3796 each to a large institutional investor for gross proceeds of about $15-million. Net proceeds of about $14.8-million will be used for general corporate purposes.
Corindus is global leader in robotic-assisted vascular interventions. Its CorPath platform is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is a second-generation robotic-assisted technology offering enhancements to the platform.
